Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

导出 OA

翻译打印收藏纠错

作者： Rakesh,Popat ^[1] ; Bradley,Augustson ^[2] ; Mercedes,Gironella ^[3] ; Cindy,Lee ^[4] ; Paul,Cannell ^[5] ; Nashita,Patel ^[6] ; Ravi S,Kasinathan ^[7] ; Rachel,Rogers ^[7] ; Mehreen,Shaikh ^[6] ; Amy,Curry ^[8] ; Fernando,Carreño ^[7] ; Sumita,Roy-Ghanta ^[7] ; Joanna,Opalinska ^[7] ; Hang,Quach ^[9]

作者单位： NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK. ^[1] Sir Charles Gairdner Hospital and Linear Clinical Research, Perth, WA, Australia. ^[2] Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain. ^[3] Royal Adelaide Hospital, Adelaide, SA, Australia. ^[4] Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia. ^[5] GSK, London, UK. ^[6] GSK, Upper Providence, PA, USA. ^[7] GSK, Durham, NC, USA. ^[8] University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia. HANG.QUACH@svha.org.au. ^[9]

DOI 10.1038/s41408-024-01155-y

PMID 39433730

发布时间 2024-10-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood cancer journal

2024年14卷1期

184页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Blood cancer journal

相似文献

Blood cancer journal

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Blood cancer journal

相似文献

Blood cancer journal

相关期刊

检索历史清除